Home / Pharmaceuticals / Cutaneous Mastocytosis Treatment Market By Drug Type (Antihistamines, Corticosteroids, Mast Cell Stabilizers, Sympathomimetic Agents, Photochemotherapy), By Pipeline Analysis (Phase III, Phase II) - Growth, Future Prospects and Competitive Analysis, 2018-2026

Cutaneous Mastocytosis Treatment Market By Drug Type (Antihistamines, Corticosteroids, Mast Cell Stabilizers, Sympathomimetic Agents, Photochemotherapy), By Pipeline Analysis (Phase III, Phase II) - Growth, Future Prospects and Competitive Analysis, 2018-2026

Published: Apr 2019 | Report Code: 59649-04-19

Industry Outlook

Cutaneous mastocytosis treatment market accounted for a market value of US$ 186.7 Mn in 2017 and projected to grow at a CAGR of 5.6% during the forecast period from 2018 to 2026. Cutaneous mastocytosis is a rare disease in which uncontrolled production of mast cells leads to skin complications such as lesions, blisters, and rashes with aggravated itching. The key causes of cutaneous mastocytosis are a mutation in KIT gene which leads to overproduction of mast cells and excess accumulation of mast cell in the skin leads to chronic as well as acute reactions. The major factors that are driving this market are raising awareness related to the disease in physicians are assisting the growth of prevalence rate and expected to further assist the growth in research & development of target-specific treatment against cutaneous mastocytosis.

Market Synopsis

Cutaneous Mastocytosis Treatment Market

Get a sample copy for more information

"Photochemotherapy has satisfactory results and it is becoming choice of treatment for most of the dermatologists in developed as well as developing countries"

Photochemotherapy (PUVA) is identified as the fastest growing segment throughout the forecast period from 2018 to 2026 due to an effective combination of drug Psoralens and long-wave ultraviolet radiation to treat cutaneous mastocytosis is accepted and practiced by several dermatologists from developed as well as developing countries. The patients initially exposed to psoralens, drugs that contain chemicals that react with ultraviolet light & later UVA light. However, Photochemotherapy sessions required for a patient suffering from cutaneous mastocytosis are in a range of 10 to 15 times in a month.

Cutaneous Mastocytosis Treatment Market

Get a sample copy for more information

"Asia Pacific is the fastest growing market due to rising awareness in dermatologists about the rare skin diseases and developing healthcare infrastructure in developing countries"

During the forecast period from 2018 to 2026, Asia Pacific identified as the fastest growing cutaneous mastocytosis treatment market mainly due to increasing awareness in dermatologists related to rare genetic disorders, and developing healthcare infrastructure is assisting the diagnosis rate. Significant economic growth in developing & developed countries of Asia Pacific has increased the overall infrastructural development including healthcare, transport, educational, and others. This has led to increasing in opportunities for local as well as migrating individuals due to which population of Caucasians is also increasing in the Asia Pacific and as the study suggests that cutaneous mastocytosis observed mainly in Caucasians.

Cutaneous Mastocytosis Treatment Market

Get a sample copy for more information

Cutaneous Mastocytosis Treatment Market

Historical & Forecast Period

The cutaneous mastocytosis treatment market analyzed considering current market trends for base year 2017 and based on future trends CAGRs calculated for the forecast period from 2018 to 2026.

Report Scope by Segments

This report covers the exhaustive study of cutaneous mastocytosis treatment market including market interpretations and assumptions analyzed based on elaborative qualitative and quantitative data segregated through primary and secondary research. Industry stakeholders through primary interviews have helped to analyze and understand market dynamics such as opportunities, drivers, & challenges further segmented to region & respective countries. This report also covers a complete study of several segments of global cutaneous mastocytosis treatment such as the type of drug class, and geography. Pipeline analysis covers information related to two molecules that are under clinical trial and expecting approval in the near future. The report also provides an understanding associated with competitive landscape of the key companies operate and present in cutaneous mastocytosis treatment market that includes company data points such as current/future business strategies, financial data, & product portfolio.

ATTRIBUTE DETAILS
Research Period  2017-2027
Base Year 2018
Forecast Period  2019-2027
Historical Year  2017
Unit  USD Million
Segmentation

 Type of Drug Class (2016–2026; US$ Mn)
 • Antihistamines
 • Corticosteroids
 • Mast Cell Stabilizers
 • Sympathomimetic Agents (Ephinephrine)
 • Photochemotherapy

 Pipeline Analysis
 • Phase III (Sales till 2026; US$ Mn)
   o Mastinib
 • Phase II (Qualitative Information)
   o TF 002

 Geography Segment (2016–2026; US$ Mn)
 • North America (U.S., Canada)
 • Europe (U.K., Germany, Rest of Europe)
 • Asia Pacific (Japan, China, Rest of APAC)
 • Latin America (Brazil, Mexico, Rest of LATAM)
 • Middle East and Africa (GCC, Rest of MEA)

The key companies currently available in the market analyzed based on recent market updates, product portfolio, financial data, and major strategies. This report also includes attractive investment proposition analyzed with the help of PESTEL analysis, which focuses on in-depth geographical research. Key companies present in the overall report are Novartis AG, Mylan NV, Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., Sanofi S.A., Johnson & Johnson, Bayer AG, and Mallinckrodt Pharmaceuticals among others.

Key questions answered in this report

  • Which drug class type is in high demand to treat cutaneous mastocytosis & Why?
  • What are the present market strategies & policies studied & applied by major market players & competitive landscape of the global cutaneous mastocytosis treatment market?
  • Which are the crucial & impending geographical markets (regions and countries) in cutaneous mastocytosis treatment market & Why?
  • Which is the largest and fastest growing region globally?
  • What will be the expected sales of drugs under pipeline?

Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Study Purpose
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase III-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted

Chapter 2. Executive Summary
2.1. Global CMT Market Portraiture
2.2. Global CMT Market, by Type of Drug Class, 2017 (US$ Mn)
2.3. Global CMT Market, by Geography, 2017 Vs 2026 (Value %)

Chapter 3. Global Cutaneous Mastocytosis Treatment (CMT) Market: Market Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Landscape
3.6.1. Competitive Landscape, by Key Players, 2017

Chapter 4. Global Cutaneous Mastocytosis Treatment (CMT) Market, by Type of Drug Class, 2016 – 2026 (US$ Mn)
4.1. Overview
4.2. Antihistamines
4.3. Corticosteroids
4.4. Mast Cell Stabilizers
4.5. Sympathomimetic Agents (Ephinephrine)
4.6. Photochemotherapy

Chapter 5. Global Cutaneous Mastocytosis Treatment (CMT) Market: Pipeline Analysis
5.1. Overview
5.2. Phase III [Till 2026] (U$ Mn)
5.2.1. Mastinib
5.3. Phase II (Qualitative Information)
5.3.1. TF 002

Chapter 6. Global Cutaneous Mastocytosis Treatment (CMT) Market, by Geography, 2016 – 2026 (US$ Mn)
6.1. Overview
6.2. North America CMT Market Analysis, 2016 – 2026
6.2.1. North America CMT Market, by Type of Drug Class, 2016–2026 (US$ Mn)
6.2.2. North America CMT Market, by Country, 2016 – 2026 (US$ Mn)
6.2.2.1. U.S.
6.2.2.2. Canada
6.3. Europe CMT Market Analysis, 2016 – 2026
6.3.1. Europe CMT Market, by Type of Drug Class, 2016–2026 (US$ Mn)
6.3.2. Europe CMT Market, by Country, 2016 – 2026 (US$ Mn)
6.3.2.1. U.K.
6.3.2.2. Germany
6.3.2.3. Rest of Europe
6.4. Asia Pacific CMT Market Analysis, 2016 – 2026
6.4.1. Asia Pacific CMT Market, by Type of Drug Class, 2016–2026 (US$ Mn)
6.4.2. Asia Pacific CMT Market, by Country, 2016 – 2026 (US$ Mn)
6.4.2.1. Japan
6.4.2.2. China
6.4.2.3. Rest of APAC
6.5. Latin America CMT Market Analysis, 2016 – 2026
6.5.1. Latin America CMT Market, by Type of Drug Class, 2016–2026 (US$ Mn)
6.5.2. Latin America CMT Market, by Country, 2016 – 2026 (US$ Mn)
6.5.2.1. Brazil
6.5.2.2. Mexico
6.5.2.3. Rest of Latin America
6.6. Middle East & Africa (MEA) CMT Market Analysis, 2016 – 2026
6.6.1. Middle East & Africa CMT Market, by Type of Drug Class, 2016–2026 (US$ Mn)
6.6.2. MEA CMT Market, by Region, 2016 – 2026 (US$ Mn)
6.6.2.1. GCC
6.6.2.2. Rest of MEA

Chapter 7. Company Profiles
7.1. Pfizer Inc.
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Product Portfolio
7.1.4. Key Developments
7.2. Merck & Co., Inc.
7.3. EPI Health, LLC.
7.4. kaleo, Inc.
7.5. Bausch Health Companies Inc.
7.6. Mylan N.V.
7.7. Sanofi
7.8. Mallinckrodt
7.9. Bayer AG
7.10. Teva Pharmaceutical Industries Ltd.
7.11. Novartis AG
7.12. Johnson & Johnson

* CMT - Cutaneous Mastocytosis Treatment

FIG. 1 : Cutaneous Mastocytosis Treatment (CMT): Market Segmentation
FIG. 2 : Global CMT Market, by Type of Drug Class, 2017 (US$ Mn)
FIG. 3 : Global CMT Market, by Geography, 2017 Vs 2026 (US$ Mn)
FIG. 4 : Attractive Investment Proposition, by Geography, 2017
FIG. 5 : Market Competition Landscape, by Key Players, 2017
FIG. 6 : Global Antihistamines Market for CMT, 2016 – 2026 (US$ Mn)
FIG. 7 : Global Corticosteroids Market for CMT, 2016 – 2026 (US$ Mn)
FIG. 8 : Global Mast Cell Stabilizers Market for CMT, 2016 – 2026 (US$ Mn)
FIG. 9 : Global Sympathomimetic Agents Market for CMT Market, 2016 – 2026 (US$ Mn)
FIG. 10 : Global Photochemotherapy Market for CMT Market, 2016 – 2026 (US$ Mn)
FIG. 11 : Global Mastinib Market for CMT, Till 2026 (US$ Mn)
FIG. 12 : U.S. CMT Market, 2016 – 2026 (US$ Mn)
FIG. 13 : Canada CMT Market, 2016 – 2026 (US$ Mn)
FIG. 14 : U.K. CMT Market, 2016 – 2026 (US$ Mn)
FIG. 15 : Germany CMT Market, 2016 – 2026 (US$ Mn)
FIG. 16 : Rest Of Europe CMT Market, 2016 – 2026 (US$ Mn)
FIG. 17 : Japan CMT Market, 2016 – 2026 (US$ Mn)
FIG. 18 : China CMT Market, 2016 – 2026 (US$ Mn)
FIG. 19 : Rest Of Asia Pacific CMT Market, 2016 – 2026 (US$ Mn)
FIG. 20 : Brazil CMT Market, 2016 – 2026 (US$ Mn)
FIG. 21 : Mexico CMT Market, 2016 – 2026 (US$ Mn)
FIG. 22 : Rest Of Latin America CMT Market, 2016 – 2026 (US$ Mn)
FIG. 23 : GCC CMT Market, 2016 – 2026 (US$ Mn)
FIG. 24 : Rest Of Middle East And Africa CMT Market, 2016 – 2026 (US$ Mn)

TABLE 1 : Global Cutaneous Mastocytosis Treatment (CMT) Market, by Type of Drug Class, 2016 – 2026 (US$ Mn)
TABLE 2 : North America CMT Market, by Type of Drug Class, 2016 – 2026 (US$ Mn)
TABLE 3 : North America CMT Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 4 : Europe CMT Market, by Type of Drug Class, 2016 – 2026 (US$ Mn)
TABLE 5 : Europe CMT Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 6 : Asia Pacific CMT Market, by Type of Drug Class, 2016 – 2026 (US$ Mn)
TABLE 7 : Asia Pacific CMT Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 8 : Latin America CMT Market, by Type of Drug Class, 2016 – 2026 (US$ Mn)
TABLE 9 : Latin America CMT Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 10 : Middle East & Africa CMT Market, by Type of Drug Class, 2016 – 2026 (US$ Mn)
TABLE 11 : Middle East And Africa CMT Market, by Region, 2016 – 2026 (US$ Mn)
TABLE 12 : Pfizer Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 13 : Merck & Co., Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 14 : EPI Health, LLC.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 15 : kaleo, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 16 : Bausch Health Companies Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 17 : Mylan N.V.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 18 : Sanofi: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 19 : Mallinckrodt: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 20 : Bayer AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 21 : Teva Pharmaceutical Industries Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 22 : Novartis AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 23 : Johnson & Johnson: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)

Choose License Type
Connect With Us
+1-800-361-8290
24/7 Research Support

Our Clients